CA 19-9 by RIA

Code
900.0800
Name
CA 19-9 by RIA
Category
None
Department
Send-Out
Start Date
Expiration Date
Synonyms
Cancer Antigen 19-9; Pancreatic Cancer Tumor Marker; Gastro-Intestinal Cancer Marker
CPT Codes
86301
Site
SBMF
Reference Test
30199
ATLAS Test Code

CA1909

Specimen Information

Type

Gold, SST

Volume

0.5 ml

Transport Info

Centrifuge and immediately transfer serum to separate plastic tube Refrigerated 48 Hours If specimen will not be received within 48 hours of collection, freeze serum and transport frozen

Fasting Required?
False
Patient Instructions

Reference Range

Less than 35 U/mL

Methodology

Chemiluminescenct Immunoassay

Clinical Significance

Aid in monitoring disease status in patients with confirmed pancreatic cancer. CA 19-9 is a tumor-associated antigen that is reactive with an antibody that was produced in response to immunization with a human colon cancer cell-line. Although the antibody was derived from a colon cancer cell-line, studies have found assays for CA 19-9 more useful in the diagnosis and management of patients with pancreatic cancer than colon neoplasia. CA 19-9 has also been shown to be a more sensitive and specific marker of pancreatic cancer than other serologic markers. Very little of the CA 19-9 antigen is found in the blood of normal patients or those with benign disorders, but most patients with pancreatic cancer have elevated levels of CA 19-9. Many published studies have shown that patients on various therapeutic regimens with clinically stable or responsive disease had stable or decreasing serum CA 19-9 levels, whereas patients with progressive disease had rising serum levels of CA 19-9. The clinical management of pancreatic cancer is extremely difficult with most pancreatic cancers having metastasized by the time of diagnosis. Treatment consists of surgical intervention, radiation therapy, chemotherapy and palliative care measures as well as nutritional management. Monitoring the progression of disease is critical in the management of this disease. Therefore, the serial monitoring of CA 19-9 levels as an adjunct to imaging and clinical assessment is valuable in the management of pancreatic cancer patients.

Back

Patients & Visitors

Make a First Appointment Maternity Pre-Registration Make a Donation Recognize a Sarah Bush Lincoln Employee